ATH-1017

DRUG4 trials

Sponsors

Athira Pharma

Conditions

Alzheimer DiseaseDementia With Lewy BodiesDementia of Alzheimer TypeParkinson Disease Dementia

Phase 2

ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

CompletedNCT04488419

Athira PharmaAlzheimer Disease, Dementia of Alzheimer Type

Start: 2020-09-28End: 2024-07-15Updated: 2025-04-04

A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease

CompletedNCT04491006

Athira PharmaAlzheimer Disease, Dementia of Alzheimer Type

Start: 2020-11-23End: 2022-05-20Updated: 2023-06-12

ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)

TerminatedNCT04831281

Athira PharmaDementia With Lewy Bodies, Parkinson Disease Dementia

Start: 2022-01-20End: 2023-04-19Updated: 2025-03-04

Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

TerminatedNCT04886063

Athira PharmaAlzheimer Disease

Start: 2021-06-30End: 2024-10-23Updated: 2025-04-01

Related Papers

Fosgonimeton in mild-to-moderate Alzheimer's disease

Journal of Alzheimer s Disease Reports2025-01-01

Neuroprotective effects of fosgonimeton and amyloid‐β‐targeting monoclonal antibodies against amyloid‐β toxicity in primary neuron culture

Alzheimer s & Dementia2024-12-01

Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease.

2024-04-092 citations

Biomarker analyses from the phase 2, randomized, placebo‐controlled ACT‐AD and open‐label extension clinical trials of fosgonimeton in patients with mild‐to‐moderate Alzheimer’s disease

Alzheimer s & Dementia2023-12-011 citations

Fosgonimeton, a Small‐Molecule Positive Modulator of the HGF/MET System, Attenuates Amyloid‐β – Mediated Toxicity in Primary Neuron Culture

Alzheimer s & Dementia2023-12-01

Fosgonimeton Provides Congruent Improvements on Neurodegeneration Biomarkers, Significantly Correlating With Composite Clinical Score of Cognition and Function in Alzheimer’s Disease (S26.008)

Neurology2023-04-253 citations

ACT‐AD: Fosgonimeton in mild‐to‐moderate Alzheimer’s disease – first results of a randomized, placebo‐controlled, 26‐week Phase 2 proof‐of‐concept trial

Alzheimer s & Dementia2022-12-013 citations

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer’s Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial

Journal of Alzheimer s Disease2022-02-1825 citations